ClinicalTrials.gg
CompletedNCT05487963Updated Feb 13, 2025

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

A Phase 1/2 interventional study of Tofacitinib Citrate and placebo ointment in Atopic Dermatitis, sponsored by CAGE Bio Inc.. Completed at 1 site in Georgia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by CAGE Bio Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of the proposed study is to evaluate the tolerability and effectiveness of a 1% topical ointment of tofacitinib for the treatment of mild to moderate atopic dermatitis in adults. Adult patients with a diagnosis of atopic dermatitis for at least 6 months will be treated with the test product or placebo for a period of 8 weeks with a follow-up visit at 12 weeks. The primary endpoints are safety and tolerability of CGB-500 Ointment and a comparison of effectiveness of CGB-500 Ointment and Vehicle Ointments in treating lesion(s) of mild to moderate atopic dermatitis.

02

Conditions studied

  • Atopic Dermatitis

Browse trials for

03

In context

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

This study's enrollment of 40 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

CAGE Bio Inc. is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Outpatient, male or female of any race, 18 years of age or older. Female subjects of must have a negative urine pregnancy test at Baseline and practice a reliable method of throughout the study.
  2. Have a clinical diagnosis of atopic dermatitis for at least 6 months prior to Day 0 (at the Screening and Baseline visit) that has been clinically stable for ≥3 months prior to dose administration and is confirmed to be atopic dermatitis according to the criteria of Hanifin and Rajka.
  3. Have an IGA score of 2 (mild) or 3 (moderate) at Day 0.
  4. Have an EASI score of 1.1 to 12.0 (i.e., mild or moderate).
  5. Have atopic dermatitis on the arms and other body parts covering at least 2% of total BSA and up to and including 12% of total Body Surface Area (BSA) at Day 0.
  6. Have a presence of 1 to 3 target atopic dermatitis lesions of total surface area of 15 to 30 cm2, located on the body part visible to the subject. This is the target lesion(s) that will be treated in this study.
  7. Agree to use only low potency (up to 1% hydrocortisone) topical cream or ointment for the other affected parts of the body that are not being treated with the product in the study, and at least 5 cm away from the treated area.
  8. In general, good health as determined by medical history and physical examination at the time of screening (Investigator discretion).
  9. Have a Peak Pruritus NRS score of ≥30 on the of scale 0 to 100, especially on the target lesions.
  10. Ability to follow study instructions and likely to complete all required visits.
  11. Have signed the Institutional Review Board (IRB)-approved Form (ICF) prior to any study-related procedures being performed.
  12. Participating in any other clinical trial from 30 days prior to Screening and throughout the planned 12-week study period.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant, breast-feeding, or of and not practicing reliable .
  2. Known or previous allergic reaction to any constituent of the Product (i.e., essential oils, choline, phosphatidylcholine, glycerol, propylene glycol, polyethylene glycol).
  3. Any transient flushing syndrome.
  4. Severe atopic dermatitis.
  5. Unstable course of atopic dermatitis (spontaneous improvement over time).
  6. Skin infections (bacterial, fungal or viral) that can interfere with reliable atopic dermatitis assessments.
  7. Basal cell carcinoma within 6 months of Baseline (Visit 1).
  8. History of confounding skin conditions, e.g., psoriasis, rosacea, erythroderma, or ichthyosis or presence of Netherton's syndrome, immunological deficiencies or diseases, , diabetes, , serious active or recurrent infection, severe renal insufficiency, or severe hepatic disorders.
  9. Use within 1 month prior to Baseline of 1) oral or intravenous , 2) UVA/UVB therapy, 3) PUVA (Psoralen plus UltraViolet A) therapy, 4) tanning booths, 5) non-prescription UV light sources, 6) immunomodulators or therapies, 7) interferon, 8) cytotoxic drugs, 9) crisaborole, 10) pimecrolimus, or 11) injectable biologics (e.g. Dupixent).
  10. Use within 14 days of Baseline of: 1) systemic antibiotics, 2) systemic JAnus Kinase (JAK) products, 3) calcipotriene or other vitamin D preparations, or 4) retinoids.
  11. Use within 7 days prior to Baseline of: 1) antihistamines, 2) topical antibiotics, 3) topical corticosteroids or 4) other topical drug products.
  12. Use within 24 hours prior to Baseline of any topical product (e.g., sunscreens, lotions, creams, emollients, moisturizers) in the areas to be treated.
  13. Known allergy or hypersensitivity to tofacitinib or any other component of the Investigational Product (i.e., essential oils, choline, phosphatidylcholine, glycerol, propylene glycol, polyethylene glycol).
  14. Uncontrolled systemic disease.
  15. Foreseen unprotected and intense/excessive UV exposure during the study.
  16. Scheduled or planned surgical procedures during the study.
  17. Unable or unwilling to comply with any of the study requirements.
  18. Medical or psychiatric conditions, or a personal situation, that may increase the risk associated with study participation or may interfere with interpretation of study results or subject compliance and, in the opinion of the Principal Investigator, makes the subject inappropriate for study entry.
  19. Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    CGB-500 topical ointment, 1% tofacitinib

    Drug: Tofacitinib Citrate

  • Placebo comparator
    Vehicle topical ointment

    Other: placebo ointment

Interventions

  • Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.

  • Otherplacebo ointment

    Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Frequency of subjects with Treatment-Emergent Adverse Events (TEAEs). • Frequency of subjects with skin irritation TEAEs and any other adverse skin reactions.

    Time frame: 8 weeks

  2. Effectiveness

    Percent change from baseline in lesional Eczema Area and Severity Index (EASI) score at Week 8. EASI is scored on a 0 - 6 scale with 0 being no eczema and 6 being 100% of the area affected by eczema.

    Time frame: 8 weeks

Secondary outcomes

  1. Investigator's Global Assessment (IGA)

    Percentage of subjects achieving Investigator's Global Assessment (IGA) response of 'Clear' (Score 0) or 'Almost Clear' (Score 1) at Week 8.

    Time frame: 8 weeks

  2. Eczema Area and Severity Index (EASI)

    Percentage of subjects who achieve a ≥75% improvement from baseline in lesional EASI score at Week 8

    Time frame: 8 weeks

  3. Pruritis

    Change from baseline in peak lesional pruritus (itching) Numeric Rating Scale (NRS) score at Week 8. NRS goes from 0 to 10; with 0 signifying no itching and 10 signifying worst itch imaginable.

    Time frame: 8 weeks

07

Study locations

1 site
  • Kani Clinic
    Tbilisi, 0160, Georgia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jun 2023, 7 months.

Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 7 months is below that.

Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2022
First posted
Aug 4, 2022
StartActual
Nov 9, 2022
Primary completionActual
Jun 30, 2023
CompletionActual
Jul 30, 2023
Last update
Feb 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05487963
Lead sponsor
CAGE Bio Inc.
Responsible party
Sponsor
First posted
Aug 4, 2022
Start date
Nov 9, 2022
Primary completion
Jun 30, 2023
Completion
Jul 30, 2023
Last update
Feb 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion